Literature DB >> 9549443

Proteases as prognostic markers in cancer.

H W Verspaget.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9549443      PMCID： PMC1112763          DOI： 10.1136/bmj.316.7134.790

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

Review 1.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

Review 2.  Biology and biochemistry of proteinases in tumor invasion.

Authors:  P Mignatti; D B Rifkin
Journal:  Physiol Rev       Date:  1993-01       Impact factor: 37.312

3.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

4.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9.

Authors:  Z S Zeng; Y Huang; A M Cohen; J G Guillem
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

5.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

6.  Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.

Authors:  G I Murray; M E Duncan; P O'Neil; W T Melvin; J E Fothergill
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

7.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

Review 8.  Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer.

Authors:  G Opdenakker; J Van Damme
Journal:  Cytokine       Date:  1992-07       Impact factor: 3.861

Review 9.  Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

Authors:  H Pappot; H Gårdsvoll; J Rømer; A N Pedersen; J Grøndahl-Hansen; C Pyke; N Brünner
Journal:  Biol Chem Hoppe Seyler       Date:  1995-05

10.  TIMP1 and adverse prognosis in non-small cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; P J Smith
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531
View more
  4 in total

Review 1.  Systemic enzyme therapy in oncology: effect and mode of action.

Authors:  J Leipner; R Saller
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  The molecular biology of colorectal cancer development and the associated genetic events.

Authors:  R M Navaratnam; J Chowaniec; M C Winslet
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

3.  A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer.

Authors:  Hatem A El-mezayen; Fatheya M Metwally; Hossam Darwish
Journal:  Tumour Biol       Date:  2013-11-13

4.  Quantitative Measurement of Protease-Activity with Correction of Probe Delivery and Tissue Absorption Effects.

Authors:  Christopher D Salthouse; Fred Reynolds; Jenny M Tam; Lee Josephson; Umar Mahmood
Journal:  Sens Actuators B Chem       Date:  2009-05-06       Impact factor: 7.460
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.